Chiropractic Rehabilitation in Detail for Testosterone Health

Learn about the innovative approach to testosterone health with chiropractic rehabilitation and its positive impact on your well-being.

Abstract

Low testosterone is often reduced to a single lab number and a single prescription. That framing misses what the hormone actually does, why a symptomatic man with a total testosterone near 370 ng/dL can still feel unwell, and how obesity, sleep apnea, opioid exposure, chronic pain, and metabolic disease pull the axis down. It also misses the difference between a signaling problem in the brain and a production problem in the testes.

This educational article explains testosterone physiology, the core labs that separate central from peripheral hypogonadism, and the limits of both low and treated testosterone. Chiropractic care does not replace testosterone and is not a direct treatment for hypogonadism. In clinical observations at Sciatica Clinic and in professional notes on LinkedIn, it helps indirectly by reducing musculoskeletal pain, restoring movement tolerance, supporting sleep, and lowering autonomic stress so that medical and functional care have a better chance to work. At Injury Medical Clinic PA in El Paso, that work is combined with massage therapy, physical therapy loading, and functional wellness under medical direction from Dr. Maria Guadalupe Cardenas, MD, a board-certified internist (NPI 1164426748; Texas medical license J2933).

A Collaborative Model, Not a Hormone Shop

Injury Medical Clinic PA uses a multidisciplinary model common in advanced injury and integrative settings. Dr. Cardenas provides medical evaluation, diagnostic oversight, and prescribing when medication is indicated. I provide chiropractic and functional medicine care and coordinate movement, nutrition, and rehabilitation plans.

The split of responsibility matters. Testosterone therapy, clomiphene, and human chorionic gonadotropin (hCG) are medical decisions. Spinal care, soft-tissue work, and graded loading are rehabilitation decisions. Patients do better when those tracks are planned together rather than stacked at random.

What Testosterone Actually Does

Testosterone is the principal androgen in men. Leydig cells in the testes make most of it after luteinizing hormone (LH) arrives from the pituitary. A smaller amount comes from adrenal precursors. In blood, most testosterone is bound to sex hormone-binding globulin (SHBG) or albumin. Only the unbound, or free, fraction readily enters muscle, bone, brain, and reproductive tissue.

In adult men, adequate testosterone supports:

• Lean mass and the response to resistance training, which is why low levels track with muscle loss.
• Bone mineral density, particularly cortical bone.
• Libido and aspects of erectile tissue health. Spermatogenesis also depends on follicle-stimulating hormone (FSH) acting on Sertoli cells.
• Red blood cell production, which is why testosterone therapy requires hematocrit monitoring.
• Insulin sensitivity and visceral fat distribution. Low testosterone and central obesity reinforce each other.
• Mood, motivation, and some aspects of cognition. These effects are real but not specific. Fatigue and brain fog have many other causes.

The Endocrine Society recommends diagnosing hypogonadism only when symptoms or signs consistent with testosterone deficiency are present, and serum testosterone is unequivocally and consistently low, measured with an accurate assay and confirmed on a repeat morning sample (Bhasin et al., 2018). The American Urological Association uses a practical threshold: symptoms plus two morning total testosterone values below 300 ng/dL (Mulhall et al., 2018).

A result of 370 ng/dL sits above that threshold. It is not, by itself, a diagnosis. It is also not automatically fine in a man in his 40s or 50s who cannot recover from training, has lost libido, and is gaining visceral fat. About 30 percent of men with a low first reading normalize on retest, so a single afternoon draw shouldn’t drive treatment (Bhasin et al., 2018). The useful question is whether symptoms, free testosterone, SHBG, estradiol, gonadotropins, sleep, and body composition tell a coherent story.

What Happens When Comorbidities Pull the Axis Down

The hypothalamic-pituitary-gonadal axis is a pulse system. The hypothalamus releases gonadotropin-releasing hormone (GnRH). The pituitary answers with LH and FSH. LH drives testicular testosterone. Testosterone and estradiol then feed back and slow the pulse. Anything that flattens GnRH pulses, or atops the testes from responding to LH, lowers testosterone.

Common comorbidities do this in predictable ways.

Obesity and insulin resistance. Adipose tissue expresses aromatase, which converts testosterone to estradiol. Higher estradiol can suppress LH. At the same time, insulin resistance lowers SHBG, so total testosterone falls even when free testosterone is less affected. Visceral fat, low activity, and poor sleep then reinforce the loop. In a controlled experiment that suppressed gonadal steroids and replaced them across a dose range, androgen deficiency accounted for loss of lean mass and strength. In contrast, estrogen deficiency accounted for the rise in body fat, and both contributed to the decline in sexual function (Finkelstein et al., 2013).

Sleep loss and obstructive sleep apnea. One week of sleep restriction to about five hours a night lowered daytime testosterone by 10 to 15 percent in young healthy men (Leproult & Van Cauter, 2011). Apnea adds intermittent hypoxia and fragmented sleep. Untreated severe apnea is also a reason to withhold testosterone therapy until it is addressed, because therapy can worsen apnea in some men (Bhasin et al., 2018).

Chronic pain, injury, and opioid exposure. Persistent nociception raises sympathetic tone and cortisol. Immobility cuts the training stimulus that maintains muscle. Opioids suppress GnRH and are a recognized cause of secondary hypogonadism. In injury practice, the endocrine problem often starts as a movement problem: the man cannot train, cannot sleep on his side, and is taking medication that flattens the axis.

Illness, medications, and pituitary disease. Glucocorticoids, hyperprolactinemia, hemochromatosis, and significant head trauma can suppress or damage the signaling pathway. Primary testicular failure, from injury, chemotherapy, orchitis, or genetic conditions, looks different on labs: testosterone is low, and LH and FSH are high.

Very low testosterone and mortality. An individual-participant meta-analysis of community-dwelling men found higher all-cause mortality when baseline testosterone was below 7.4 nmol/L (about 213 ng/dL), and higher cardiovascular mortality below 5.3 nmol/L (about 153 ng/dL), after adjustment for other risk factors (Yeap et al., 2024). High LH above 10 IU/L and very low estradiol were also associated with higher all-cause mortality. These are associations, not proof that raising a mid-range level extends life. They do argue against dismissing clearly low values in a symptomatic man.

Central Versus Peripheral: Why the Pattern Changes the Plan

Secondary, or central, hypogonadism means the pituitary is not sending enough LH and FSH. Clues are low or inappropriately normal gonadotropins with low testosterone. Drivers include obesity, apnea, opioids, hyperprolactinemia, and chronic illness. The first job is to remove the suppressors. Fertility-preserving medical options, such as clomiphene or hCG, are considered when endogenous production can still be stimulated.

Primary, or peripheral, hypogonadism means the testes are not responding. LH and FSH rise. Causes include testicular injury, chemotherapy, radiation, and some genetic conditions. Stimulation strategies have less to offer. Replacement may be appropriate after a full risk discussion.

The Endocrine Society recommends measuring LH and FSH once testosterone deficiency is confirmed, so the cause isn’t left a mystery (Bhasin et al., 2018).

The Labs That Actually Classify the Problem

A practical first panel, drawn in the morning on two separate days when the first value is low, includes:

• Total testosterone, by an accurate assay.
• SHBG, with free testosterone by equilibrium dialysis or a validated calculation.
• LH and FSH.
• Estradiol, preferably by a sensitive assay when the result will change management.
• Prolactin, when central hypogonadism, low libido, or headache is present.
• TSH and free T4, because thyroid status changes SHBG and energy.
• CBC, comprehensive metabolic panel, lipids, HbA1c, and a fasting insulin or similar insulin-resistance marker.
• Hematocrit and prostate-specific antigen before any testosterone prescription, then on a schedule (Mulhall et al., 2018).

High SHBG can leave a man symptomatic with a mid-range total testosterone and a low free fraction. Low SHBG, common in insulin resistance, can make total testosterone look worse than the free fraction. Treating the number without the binding protein is how plans go wrong.

Pituitary imaging is not routine. It is considered when prolactin is high, testosterone is severely low, or there are headaches or visual changes.

Delivery Method, Estradiol, and Cardiovascular Risk

Route is a medical decision, not a clinic slogan. Injections of testosterone cypionate or enanthate give predictable exposure and can be split into smaller, more frequent doses to blunt peaks. Gels and creams avoid injection but vary in absorption and can transfer to partners or children. Pellets, nasal gel, and buccal tablets are niche options that require their own monitoring

Estradiol is not a toxin. Men need some estradiol for bone, fat distribution, and sexual function (Finkelstein et al., 2013). Excess estradiol can contribute to fluid retention and breast tenderness, and it participates in negative feedback. First-line corrections include fat loss, reduced alcohol, improved sleep, and dose or frequency adjustments. An aromatase inhibitor is a second-line medical decision, not a default add-on.

On cardiovascular risk, the TRAVERSE trial found testosterone therapy noninferior to placebo for major adverse cardiac events in men 45 to 80 years old with hypogonadism and preexisting or high cardiovascular risk (Lincoff et al., 2023). That does not make therapy risk-free. Erythrocytosis, worsening apnea, fertility loss, and prostate evaluation still require monitoring (Bhasin et al., 2018). Exogenous testosterone suppresses sperm production. Men who want near-term fertility should not be started on replacement without a fertility plan.

How Chiropractic Care Fits, and Where It Does Not

Chiropractic care does not stimulate Leydig cells, and an adjustment is not a testosterone prescription. I do not use spinal manipulation as a treatment for hypogonadism. The link is indirect, and I see the same link in injury care at Sciatica Clinic.

Chronic lumbar or sciatic pain fragments sleep, cuts walking and lifting, and keeps sympathetic tone high. Patients describe the pattern in clinic: pain pills elsewhere, no change in the mechanical driver, then weight gain and a flat morning. On LinkedIn, the professional notes from this practice make the same point. Neuromusculoskeletal care changes what the man can do. It does not replace the endocrine workup.

What chiropractic care can change, when the exam supports it:

• Nociceptive load from a stiff or irritated spinal segment, so sleep and training become possible again.
• Regional mechanics at the lumbar spine, pelvis, and hip, which matter for squatting, hinging, and walking without a protective limp.
• Breathing and postural tolerance, which affect nocturnal comfort in men already at risk for apnea.
• Confidence to load tissue, which is a prerequisite for the resistance training that supports body composition.

Those are rehabilitation outcomes. Any later change in testosterone is downstream of sleep, fat mass, medication exposure, and medical therapy, not a direct effect of the adjustment.

Signs of Hormonal Imbalances In Men *THIS IS WHY*- Video

Combined With Massage, Physical Therapy, and Functional Wellness

The nonsurgical plan works when each discipline has a job.

Chiropractic care addresses joint motion, segmental irritation, and the movement screen. The goal is a spine and pelvis that tolerate daily load, not a promise of hormone change.

Massage therapy addresses muscle guarding, trigger points, and the protective tone that follows disc or joint pain. Patients at Sciatica Clinic often report that soft-tissue work is what lets them sit and walk long enough to start a loading program. Massage is symptom care and recovery care. It is not endocrine therapy.

Physical therapy provides the tissue stimulus testosterone-responsive muscle needs: progressive resistance, hip and trunk stability, and a graded return to lifting. A man who cannot hinge without leg pain will not sustain the training that improves insulin sensitivity and fat mass. Therapy dosing should respect tendon and disc irritability. Early aggressive loading in an irritable radiculopathy backfires.

Functional wellness covers the levers with the best evidence for the axis itself: consistent sleep timing, evaluation for apnea, resistance training three to four days a week once pain allows, protein intake adequate for training, alcohol reduction, and repletion when labs show a deficit. Correct vitamin D deficiency and low zinc status because they are common and correctable. They are not a substitute for indicated medical therapy. Weight loss in men with obesity and low testosterone often raises endogenous levels; that is a metabolic effect, not a chiropractic effect.

Medical oversight sits over the whole plan. Under Dr. Cardenas, that may include clomiphene in selected men with secondary hypogonadism who want to preserve fertility, hCG when testicular stimulation is the goal, or testosterone replacement when stimulation is inappropriate or has failed. Peptides discussed in wellness marketing, including kisspeptin and growth-hormone secretagogues, are not routine hypogonadism treatment and are not a substitute for guideline-based care. If they are considered at all, they require the same prescribing physician, the same monitoring, and a clear reason.

A typical combined sequence in this clinic looks like this. Morning labs and a musculoskeletal exam happen together. Red-flag weakness, bowel or bladder change, or progressive neurologic loss is referred, not adjusted. We treat mechanical pain with chiropractic care and massage so the patient can sleep and walk. Physical therapy adds hinge, squat, and carry progressions. Functional wellness targets apnea, protein, and alcohol. Medical therapy is added only when the diagnosis is confirmed and the goal, including fertility, is explicit. Recheck labs and symptoms in about six to eight weeks, then again at three to six months.

Clinical Observations From This Practice

These are observations, not trial results. Men referred for sciatica or post-injury back pain often arrive with fragmented sleep, reduced activity, central weight gain, and low or low-normal morning testosterone. After lumbosacral care, soft-tissue work, and graded loading, I first see changes in pain tolerance, sleep continuity, and the ability to train. Energy and mood often follow changes in sleep. Hormone labs, when they improve, do so in men who also lost visceral fat, stopped or reduced opioids, or started indicated medical therapy. I do not see adjustments alone normalize a primary testicular failure.

The pattern is described across patient-education material at Sciatica Clinic and in ongoing clinical notes shared on LinkedIn. The practical lesson is consistency: mechanical care without labs misses a suppressible endocrine driver, and a prescription without a plan for pain and sleep leaves the original suppressors in place.

What Success Looks Like

Success is not a single target such as 800 or 1,000 ng/dL. It is symptoms that match the man in front of us, free testosterone interpreted with SHBG, estradiol in a range that supports bone and sexual function without driving tenderness or fluid retention, a stable hematocrit, and the capacity to train. On the rehabilitation side, that means less pain with sitting and lifting, a walking program the patient actually keeps, and sleep long enough to matter (Leproult & Van Cauter, 2011).

Closing Perspective

When testosterone drops, the number signals metabolic health, sleep, medication exposure, and whether the body can still move. Chiropractic care fits into that picture by removing mechanical barriers to sleep and training, combined with massage, physical therapy, and functional wellness, and placed under medical direction when hormone therapy is on the table. At Injury Medical Clinic PA, Dr. Cardenas provides that medical oversight, and the rehabilitation plan is built around the same goal: restore the conditions under which the axis, and the man, can recover.

References

• Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://doi.org/10.1210/jc.2018-00229
• Finkelstein, J. S., Lee, H., Burnett-Bowie, S.-A. M., Pallais, J. C., Yu, E. W., Borges, L. F., Jones, B. F., Barry, C. V., Wulczyn, K. E., Thomas, B. J., & Leder, B. Z. (2013). Gonadal steroids and body composition, strength, and sexual function in men. The New England Journal of Medicine, 369(11), 1011–1022. https://doi.org/10.1056/NEJMoa1206168
• Leproult, R., & Van Cauter, E. (2011). Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA, 305(21), 2173–2174. https://doi.org/10.1001/jama.2011.710
• Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., Jr., Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M. G., Snabes, M. C., Chan, A., Dubcenco, E., … Nissen, S. E. (2023). Cardiovascular safety of testosterone-replacement therapy. The New England Journal of Medicine, 389(2), 107–117. https://doi.org/10.1056/NEJMoa2215025
• Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., Platz, E. A., Ramanathan, L. V., & Lewis, R. W. (2018). Evaluation and management of testosterone deficiency: AUA guideline. The Journal of Urology, 200(2), 423–432. https://doi.org/10.1016/j.juro.2018.03.115
• Yeap, B. B., Marriott, R. J., Dwivedi, G., Adams, R. J., Antonio, L., Ballantyne, C. M., Bauer, D. C., Bhasin, S., Biggs, M. L., Cawthon, P. M., Couper, D. J., Dobs, A. S., Flicker, L., Handelsman, D. J., Hankey, G. J., Hannemann, A., Haring, R., Hsu, B., Martin, S. A., … Wittert, G. A. (2024). Associations of testosterone and related hormones with all-cause and cardiovascular mortality and incident cardiovascular disease in men: Individual participant data meta-analyses. Annals of Internal Medicine, 177(6), 768–781. https://doi.org/10.7326/M23-2781

SEO tags: testosterone, hypogonadism, central hypogonadism, peripheral hypogonadism, LH, FSH, free testosterone, estradiol, aromatase, SHBG, TRT, injections, transdermal testosterone, clomiphene, hCG, kisspeptin, CJC-1295, ipamorelin, functional medicine, chiropractic care, integrative medicine, El Paso, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas, Dr. Alex Jimenez, sciatica, rehabilitation, endocrine health, men’s health, longevity